Jon Stonehouse, BioCryst CEO
February 22, 2023 07:21 AM EST
R&D

An­oth­er BioCryst Fac­tor D in­hibitor hits clin­i­cal de­lay two months af­ter first one dis­con­tin­ued

Katherine Lewin

News Reporter

BioCryst’s most ad­vanced ex­per­i­men­tal drug in its cur­rent pipeline has hit a snag, the com­pa­ny said Tues­day as part of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

A service from the Financial Times